US officials have declared the Johnson & Johnson Covid-19 vaccine to be safe and effective. In a US based trial of over 43,000 people, the shot was deemed 72% effective. In the trial there were no Covid-19 related deaths in the vaccinated group and there were no other significant safety concerns. The J&J vaccine however has been found to be less effective against new strains of the virus found in South Africa and Latin America.
If the shot is approved for emergency use soon, Johnson & Johnson says they will be able to provide 4 million doses, short of the 12 million the company initially said they could deliver. The J&J shot is a single shot that can be stored at regular refrigerator temperatures for up to three months. It is different from the Moderna and Pfizer vaccine in that it is developed from a cold virus which helps the body develop an immune system response in order to prepare for Covid-19.
Side effects of the shot are typical fever, fatigue, headache, and pain at the injection site. No safety concerns were present for any particular group based on age, race, or ethnicity. J&J plans to offer the vaccine to anyone in their trial that received the placebo.
For more updates be sure to check back with the ABN Blog regularly.